Risk of Alzheimer's disease and duration of NSAID use

Neurology

Volumn 48, Issue 3, 1997, Pages 626-632

  Stewart, Walter F ^a   Kawas, Claudia ^b,c   Corrada, Maria ^b   Metter, E Jeffrey ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL PROTOCOL; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SELF REPORT;

EID: 0030897133     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.3.626     Document Type: Article

References (37)

1. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120: 885-890.
2. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc Natl Acad Sci USA 1985;82: 4245-4249.
3. Altstiel L, Sperber K. Cytokines in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:481-495.
4. Kitaguchi N, Takahashi T, Oishi K, Shiojiri S, Tokushima Y, Utsunomiya T, Ito H. Enzyme specificity of proteinase inhibitor region in amyloid precursor protein of Alzheimer's disease: different properties compared with protease nexin I. Biochim Biophys Acta 1990;1038:105-113.
5. Abraham CR, Shirahama T, Potter H. The protease inhibitor α1-antichymotrypsin is associated solely with amyloid deposits containing the β-protein and is localized in specific cells of both normal and diseased brains. Neurobiol Aging 1990;11: 123-129.
6. Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques: an immunohistochemical study. Acta Neuropathol (Berl) 1982;57:239-252.
7. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 1989;107:341-346.
8. McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987;79:195-200.
9. Anonymous. The Canadian Study of Health and Aging: Risk factors for Alzheimer's disease in Canada. Neurology 1994;44: 2073-2080.
10. Breitner JCS, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease. Neurology 1994;44:227-232.
11. Breitner JCS, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995;16:523-530.
12. Lucca U, Tettamanti M, Forloni G, Spagnoh A. Nonsteroidal antiinflammatory drug use in Alzheimer's disease. Biol Psychiatry 1994;36:854-856.
13. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MMB, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? Neurology 1995;45:1441-1445.
14. Kukull WA, Larson EG, Stergachis A, et al. Non-steroidal anti-inflammatory drug use and risk of Alzheimer's disease (abstract). Neurology 1994;44(suppl 2):A237.
15. Shock N, Greulich R, Andres R, et al. Normal human aging: the Baltimore Longitudinal Study of Aging (NIH Publication No. 84-2450). Washington, DC: US Government Printing Office, 1984.
16. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile changes in the cerebral gray matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
17. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
18. Grober E, Buschke H. Genuine memory deficits in dementia. Dev Neuropsychol 1987;3:13-16.
19. Kaplan E, Goodglass H, Weintraub S. The Boston Naming Test. Boston, MA: Kaplan and Goodglass, 1978.
20. Benton AL. Differential behavioral effects in frontal lobe disease. Neuropsychologia 1968;6:53-60.
21. Army Individual Test Battery. Manual of directions and scoring. Washington, DC: War Department, Adjuvant General's Office, 1944.
22. Rouleau I, Salmon DP, Butters N, Kennedy C, McGuire K. Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease. Brain Cogn 1992;18: 70-87.
23. Morris JC, Mohs R, Rogers H, Fillenbaum G, Heyman A. Consortium to establish a Registry for Alzheimer's Disease (CERAD): clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull 1988;24:641-652.
24. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1: 385-401.
25. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982;37:323-329.
26. Nelson HE, O'Connell A. Dementia: the estimation of premorbid intelligence using the New Adult Reading Test. Cortex 1978;14:234-244.
27. Kawas C, Segal J, Stewart WF, Corrada M, Thai L. A validation study of the Dementia Questionnaire. Arch Neurol 1994; 51:901-906.
28. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed, rev. Washington, DC: American Psychiatric Association, 1987.
29. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
30. Cox DR. Regression models and life tables. J Royal Stat Society, Series B 1972;34:187-220.
31. Gilbert ES, Marks S. An analysis of mortality of workers in a nuclear facility. Radiation Res 1979;79:122-148.
32. Checkoway H, Pearce NE, Crawford-Brown DJ. Research methods in occupational epidemiology, monographs in epidemiology and biostatistics, vol 13. New York: Oxford University Press, 1989:153-155.
33. Aspirin Myocardial Infarction Study Group. A randomized controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980;243:661-669.
34. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and other non-steroidal antiinflammatory drugs. N Engl J Med 1994; 331:1675-1679.
35. Paulas HE. Nonsteroidal anti-inflammatory drugs. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. A textbook of rheumatology. Philadelphia: WB Saunders, 1989.
36. Corrada M, Stewart W, Kawas C. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease [abstract]. Neurology 1996;46(suppl 2):A433.
37. Borne RF. Nonsteroidal anti-inflamatory drugs. In: Foye WO, Lemke TL, Williams DA, eds. Principles of medicinal chemistry. 4th ed. Media, PA: Williams & Wilkins, 1995.